Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,117.08 -5.92 (-0.53%)
Streaming Delayed Price Updated: 3:41 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
Via AB Newswire
News headline image
2025 R&D Spending And Intensity Benchmarks
Via PRLog
Topics Supply Chain
News headline image
VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology
Via AB Newswire
Topics Artificial Intelligence
News headline image
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
News Provided by USA News Group on behalf of MindWalk Holdings Corp. 
From USA News Group
Via GlobeNewswire
News headline image
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
From Equity Insider
Via GlobeNewswire
News headline image
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
News Provided by USA News Group on behalf of Conexeu Sciences Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
As Medicare’s New GLP-1 Coverage Begins, Ozari Health Publishes 2026 Guide Comparing Every Way to Get Semaglutide and Tirzepatide – From $50 Copays to $86 Cash-Pay Options
Via AB Newswire
News headline image
Dr. Danielle Carrera’s Beyond Better, Thrive Debuts as Amazon #1 New Release and Top 5 Bestseller
Via Get News
News headline image
A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
From Biotech Insider
Via GlobeNewswire
News headline image
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) recently achieved what many biotechnology companies spend... 
Via Newsfile
News headline image
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Recent Industry Activity Reinforces the Need for Manufacturing Resilience, Diversified Vaccine Supply, and Health Security Amid an Evolving Global Biothreat Landscape 
Via TheNewswire.com
News headline image
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
News headline image
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
Analysts project billions in future market value as biotech innovation and consumer demand continue driving the next wave of health performance products 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors 
From MarketNewsUpdates.com
Via GlobeNewswire
BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly
Via Investor Brand Network
The Next Generation of the GLP-1 Revolution Is Already Underway
Via Investor Brand Network
News headline image
The Next Generation of the GLP-1 Revolution Is Already Underway
From BioMedWire
Via GlobeNewswire
News headline image
Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Via Get News
Topics Intellectual Property
News headline image
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)
Via Get News
Topics Intellectual Property
News headline image
Expert Matchmaker in Indianapolis Report by CX Research Institute
Via AB Newswire
Topics Economy
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
From Equity Insider
Via GlobeNewswire
News headline image
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Via Get News
Topics Intellectual Property
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Targets MASLD and GLP-1 Imaging Bottleneck With TAEUS® as Stocks Under $5 Gain Attention Inside
Via AB Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>